Nexvax2 is currently in Phase 1. Hopefully the results are encouraging. http://www.immusant.com/nexvax2/ Nexvax2® is one of an emerging class of therapeutic vaccines based on the same principles as “traditional” desensitization therapy for allergic conditions using whole proteins (ref. 4, 5). Peptide-based therapeutic vaccines have been successful in preventing and treating immune diseases in the laboratory (ref. 4). Major international programs are underway to discover and develop peptide-based therapeutic vaccines for multiple sclerosis, Type-1 diabetes, rheumatoid arthritis, and various allergic diseases including cat-sensitive asthma (ref. 4). However, discovery of relevant peptides causing human immune diseases has hindered pharmaceutical development of peptide-based therapeutic vaccines. Nexvax2® evolved from studies in patients with celiac disease who consumed gluten to deliberately reactivate the gluten immune response in a controlled manner. (ref. 9, 10) ImmusanT’s scientists identified gluten-derived peptides recognized by disease-causing immune cells (T cells) in volunteers with celiac disease after they ate gluten. It was discovered that celiac disease is uniquely suited for a peptide-based therapeutic vaccine because patients with the most common genetic version of the condition, who possess HLA DQ2, consistently have disease-causing T cells recognizing three short gluten peptides. (ref. 14) Nexvax2® has been designed for celiac disease associated HLA DQ2, present in 90% of individuals with celiac disease (ref. 6–8). Nexvax2® encompasses three peptides that account for a substantial proportion of the T-cell reaction to gluten in patients with HLA DQ2-associated celiac disease. ImmusanT’s scientists converted these peptides into a pharmaceutical agent, Nexvax2®. In laboratory studies, Nexvax2® is capable of inducing immune tolerance to gluten. ImmusanT is in clinical trials testing whether Nexvax2® induces immune tolerance to gluten and protects the intestine from the damaging effects of gluten.